Operate · FDA readiness
FDA Expedited Pathways Compared
What each FDA expedited program is, who qualifies, the main benefit and when to request it. Last updated 2 October 2026.
Comparison
Six programs, side by side.
| Program | What it is | Eligibility | Main benefit | When to request |
|---|---|---|---|---|
| Fast Track | Designation that speeds development and review of drugs for serious conditions. | Serious condition, with nonclinical or clinical data showing potential to address an unmet medical need. | More frequent FDA meetings and rolling review of the marketing application. | With the IND or any time after, ideally before the pre-NDA or pre-BLA meeting. |
| Breakthrough Therapy | Designation for drugs that may substantially improve on available therapy. | Serious condition, with preliminary clinical evidence of substantial improvement on a clinically significant endpoint. | All Fast Track features plus intensive FDA guidance and senior FDA involvement. | With or after the IND, ideally no later than the end-of-Phase 2 meeting. |
| Accelerated Approval | Approval pathway based on a surrogate or intermediate clinical endpoint. | Serious condition, meaningful advantage over available therapy, and an endpoint reasonably likely to predict clinical benefit. | Earlier approval. Confirmatory trials are required and FDA can require them to be underway before approval. | Agree endpoints and confirmatory trial plans early, typically at end-of-Phase 1 or end-of-Phase 2 meetings. |
| Priority Review | Shorter FDA review timeline for the marketing application. | A significant improvement in safety or effectiveness for a serious condition. | Six-month review goal instead of the standard ten months. | Requested with the NDA or BLA submission. FDA decides at filing. |
| Rare Pediatric Disease PRV | Priority review voucher granted at approval for a rare pediatric disease product. Program reauthorized through September 2029. | Serious or life-threatening disease that primarily affects patients under 18 and is rare in the US. | A voucher for priority review of a later application, which can be sold or transferred. | Request rare pediatric disease designation before submitting the NDA or BLA, ideally early in development. |
| Commissioner's National Priority Voucher (CNPV, pilot) | FDA pilot program granting vouchers to products aligned with US national health priorities. | Products that address national priorities defined by FDA for the pilot. Selection is at FDA's discretion. | A substantially faster review target and enhanced communication with FDA. | Apply through FDA's pilot process before or during submission planning. Check current FDA guidance, as the pilot is evolving. |
Always confirm current requirements in FDA guidance before planning a request.
Considering the CNPV pilot? Read our guide: FDA National Priority Voucher (CNPV): Should You Apply?
FAQ
FDA expedited pathway questions.
Can a program hold more than one FDA expedited designation?
Yes. Fast Track, Breakthrough Therapy, Priority Review and Accelerated Approval are not mutually exclusive, and a single program can qualify for several of them.
What is the difference between Fast Track and Breakthrough Therapy?
Fast Track can rest on nonclinical or clinical data showing potential to address an unmet need. Breakthrough Therapy requires preliminary clinical evidence of substantial improvement over available therapy and brings more intensive FDA guidance.
Is the Rare Pediatric Disease priority review voucher still available?
Yes. The Rare Pediatric Disease PRV program has been reauthorized through September 2029.
How do investors view expedited designations in diligence?
Designations signal FDA agreement on unmet need and can shorten timelines, but diligence still tests the evidence, CMC readiness and confirmatory trial plans behind them. PXM assesses these as part of the PXM Score.